Gilead buys Nimbus’s NASH portfolio
Tuesday, April 5, 2016 - 15:40
in Health & Medicine
$400 million deal adds ACC inhibitors to Gilead’s liver disease pipeline
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via